Poster Spotlight 10: Novel Combinations with Endocrine Therapy

Moderator

Erika Hamilton, Sarah Cannon Research Institute, Nashville, TN

Presentation numberPD10-01

Elacestrant alone or in combination with triptorelin in premenopausal women with ER+/HER2- early breast cancer: primary analysis from the phase 2 SOLTI-2104- PremiÈRe trial

Meritxell Bellet, Vall d'Hebron Institute of Oncology (VHIO), Hospital Universitari Vall d’Hebron / Medicine Department, Autonomous University / SOLTI Breast Cancer Research Group, Barcelona, Spain

Presentation numberPD10-02

I- SPY2 Endocrine Optimization Pilot (EOP): Neoadjuvant vepdegestrant monotherapy or in combination with letrozole or abemaciclib in molecularly selected patients with stage 2/3 HR+ HER2-negative breast cancer (BC)

Jo Chien, University of California San Francisco, San Francisco, CA

Presentation numberPD10-03

Subgroup analyses of VERITAC-2: A phase 3 trial of vepdegestrant, a PROTAC estrogen receptor (ER) degrader, versus fulvestrant in ER-positive/ human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer (aBC)

Erika P Hamilton, Sarah Cannon Research Institute, Nashville, TN

Presentation numberPD10-04

Visual functioning and characterization of visual effects from SERENA-6, a Phase 3 study of switch to camizestrant (CAMI) from aromatase inhibitor (AI) while continuing CDK4/6 inhibitor (CDK4/6i) at emergence of ESR1 mutations (ESR1m) during first-line therapy for patients (pts) with HR+/HER2− advanced breast cancer (ABC)

Adam Brufsky, UPMC Magee-Womens Hospital, Pittsburgh, PA

Presentation numberPD10-05

(z)-endoxifen maintains erα antagonist function against esr1 mutants via inactive conformation stabilization and reversal of mutant esr1-associated transcriptional signatures

Sandra S Hammer, Atossa Therapeutics Inc., Seattle, WA

Presentation numberPD10-06

Discussant: Targeting ER with Novel Agents

Andrew Davis, Washington University in St. Louis, St. Louis, MO

Presentation numberPD10-07

Efficacy of mutant-selective PI3Kα inhibitor RLY-2608 in combination with fulvestrant in patient (pt) subset populations, including pts with PIK3CA-mutant HR+/HER2- advanced breast cancer (BC) pre-treated with fulvestrant or other SERD

Cristina Saura, Vall d'Hebron University Hospital. Vall d'Hebron Institute of Oncology (VHIO), Hospitalet De Llobregat, L', Spain

Presentation numberPD10-08

Interim safety in the inavolisib + ribociclib or abemaciclib + fulvestrant or letrozole arms of MORPHEUS-pan breast cancer: A Phase 1b/2 study of efficacy and safety of multiple treatment combinations in patients with advanced breast cancer

Einav Nili Gal-Yam, Jusidman Cancer Hospital, Sheba Medical Center, Ramat-Gan, Israel

Presentation numberPD10-10

A Multicenter, Open-Label, Phase 2 Study of nab-Sirolimus (HB1901) Plus Endocrine Therapy in HR+/HER2- Advanced Breast Cancer Following Standard Therapy Failure

Fei Ma, China Cancer Institute and Hospital, Beijing, China

Presentation numberPD10-11

Differential Benefit to Elacestrant in A Large Cohort of ER+ HER2- Breast Cancer: Impact of ESR1 Mutants and Prior Therapy

George Sledge, Caris Life Sciences, Phoenix, AZ

Presentation numberPD10-12

Discussant: Targeting Endocrine Therapy Resistance with Combination Therapy

Reshma L Mahtani, Baptist Health Miami Cancer Institute, Miami, FL